Difgen Pharmaceuticals Acquires Aveva Drug Delivery Services Inc; Strengthens Its Position in Offering Difficult and Differentiated Pharmaceuticals Dosage Forms with a US-based Development and Manufacturing Capability

DifGen Pharmaceuticals has acquired Aveva Drug Delivery Services to expand its R&D and manufacturing capabilities in complex drug-device combination Transdermal Drug delivery systems and thin film-based products. The acquisition allows DifGen to secure supply and provide affordable medication to patients with the highest quality. This is DifGen’s first pharmaceutical manufacturing base in the US. Norton Rose Fulbright US LLP represented DifGen Pharmaceuticals in this transaction.

DifGen Pharmaceuticals LLC (“DifGen”) announced today that it has acquired Aveva Drug Delivery Services Inc. (“Aveva”) a fully integrated developer and manufacturer of Transdermal Delivery Systems (TDS) and Oral Dissolvable Films (ODF).

Ramandeep Singh Jaj, Founder and Co-CEO of DifGen commented “The acquisition of Aveva Drug Delivery Services Inc with its 300 plus employees marks an important milestone for DifGen as it adds its first pharmaceutical manufacturing base in the US. This strategic investment allows us to expand our R&D & manufacturing capabilities in offering complex dosage forms and secure supply to our valuable partners with local US based manufacturing. Most importantly, it will provide patients affordable lifesaving medication with highest quality and consistent supply”.

Dr. Santhanakrishnan Srinivasan, Founder and Co-CEO of DifGen commented “We are excited to bring Aveva DDS as an integral part of the DifGen family. With it’s world class development and manufacturing infrastructure and top of the line scientific talent, Aveva DDS acquisition expands our R&D infrastructure to include a highly capital intensive and complex drug-device combination Transdermal Drug delivery systems and thin film based products, areas that complement our existing infrastructure but also require specialized formulation and processing capabilities as well as specialized equipments. These formulations comprise single or multi-layered designs exhibiting a complex set of performance attributes, including uniquely controlled delivery profiles, adhesion, physical characteristics, and a variety of analytical testing requirements. TDS follows a complex set of regulatory and clinical requirements, and device design requirement that the scientific and operations team at Aveva DDS is adept at”.